ArticleRespiratory research2026
Evaluating Alpha-1 Antitrypsin Deficiency testing across Europe to ensure diagnostic accuracy: an EARCO multicentre project.
Article in Respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlpha-1 Antitrypsin Deficiency (AATD) is a rare, underdiagnosed genetic disorder caused by pathogenic variants of the SERPINA1 gene, which can lead to reduced levels and/or dysfunctional forms of the Alpha-1 Antitrypsin (AAT) protein. Accurate AATD diagnosis is critical due to its implications for pulmonary and hepatic health. However, diagnostic practices vary across laboratories, particularly in the detection and reporting of rare variants. This study aimed to evaluate the consistency and reliability of AATD diagnostic testing across European laboratories through a non-commercial external quality assessment (EQA)-like initiative.
methodsSeven European laboratories participated in six assessment rounds between 2019 and 2021. Each round involved blinded analysis of serum and dried blood spot (DBS) samples using local standard operating procedures. Tests included AAT and C-reactive protein quantification, isoelectric focusing for AAT phenotyping, and genotyping/sequencing for common and rare SERPINA1 variants. Interrater agreement was assessed using Fleiss' kappa statistic. Allele error rates were calculated for each variant and Kruskal-Wallis tests were used to compare AAT concentrations across laboratories.
resultsFor common variants (M [normal], S [p.E288V], and Z [p.E366K]), interlaboratory concordance was high, with Fleiss' kappa values indicating almost perfect agreement (0.85-1.00). Genotyping and sequencing error rates for these variants were zero. However, detection of rare variants (e.g., M
conclusionsThis initiative demonstrated strong interlaboratory agreement in detecting common AATD variants but revealed challenges in identifying and reporting rare variants. The findings support the need for SERPINA1 sequencing in AATD diagnostics and the adoption of standardised nomenclature. Centralised testing in validated reference laboratories is also recommended to ensure diagnostic accuracy and consistency across Europe.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.